Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market by GBIResearch

VIEWS: 258 PAGES: 108

More Info
									   Gout Therapeutics Market to 2017- Entry of Novel Therapies
    such as Krystexxa, Uloric, Adenuric and Colcrys to Drive
                             Market
 Reference Code: GBIHC099MR                                                                                               Publication Date: April 2011


                                      High Growth Rate and Launch of High Priced Drugs Have Made the Gout Therapeutics
     The gout therapeutics            Market Attractive
     market is expected to
     grow at a CAGR of 16.3%          The global gout therapeutics market is a fast growing market. In 2010, the global gout therapeutics
     between 2010 and 2017            market was worth $542.6m in terms of revenue, which is forecast to grow to $1,561.3m by 2017,
                                      showing a growth rate of 16.3% between 2010 and 2017. The prevalence of gout has been
                                      increasing continuously since 2002. Consequently, the gout therapeutics market has been growing
                                      at a rapid pace over the years, and is expected to accelerate in the coming years. Furthermore, the
                                      launch of expected blockbuster drugs such as TMX 67 and Krystexxa, along with the presence of a
                                      few promising biologics in the late drug development stage, would drive this growth. As a result, the
                                      market will continue to remain fast growing, thereby attracting major pharmaceutical companies to
                                      this therapy area.

                                        Gout Therapeutics Market, Global, Revenue Forecasts, ($m), 2002-2017

                                                             1,800


                                                             1,600

                                                                                                CAGR (2010-2017): 16.3%
                                                             1,400


                                                             1,200
                                              Revenue ($m)




                                                             1,000


                                                              800


                                                              600    CAGR (2002-2010): 7%



                                                              400


                                                              200


                                                                0
                                                                     2002                           2010                          2017


                                        Source: GBI Research, American College of Rheumatology, CDC

                                      The gout therapeutics market is expected to grow at a CAGR of 16.3% between 2010 and 2017.
                                      Limited Number of Approved Therapies Would Create Concentrated Patient Pools
                                      The number of gout patients is increasing year on year, and currently there are only three approved
                                      drugs in the market – Colcrys (colchicine), TMX 67 (febuxostat) and Krystexxa (pegloticase). Better
                                      efficacy and safety profiles of these drugs over generics such as non-steroidal anti inflammatory
                                      drugs (NSAID), corticosteroids, allopurinol and probenecid create a remarkable scope for gout
                                      therapeutics in the future. There is a sharp increase in the number of patients who are unable to
                                      respond to the conventional treatment for chronic gout. Therefore Krystexxa could target a more
                                      focused patient pool, refractory to conventional allopurinol therapy, thereby providing a better
                                      alternative biologic treatment option.




Gout Therapeutics Market to 2017- Entry of Novel Therapies                                                            GBIHC099MR /Published APR 2011
such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market
                                                                                                                                                Page 1
                                                                                 © GBI Research. This is a licensed product and is not to be photocopied
                                      Strategic Consolidations Have Led to the Entry of New Players in the Musculoskeletal
                                      Disorders Therapeutics Market
                                      In the past five to six years many pharmaceutical companies have improved their product profiles
                                      with respect to the musculoskeletal disorders therapeutics market. This is due to strategic deals
                                      with the aim of introducing new products with better efficacy and safety profiles into the market.
                                      Many pharmaceutical companies have either acquired or signed licensing deals with companies
                                      possessing potential products for the gout therapeutics market. The acquisitions of worldwide rights
                                      of Pegsiticase from EnzymeRx by 3SBio, and the pharmaceutical products portfolio from
                                      AstraZeneca by BioPhausia, have been the major acquisitions in the gout therapeutics market.
                                      Under licensing agreements the highest valued deal was a licensing agreement between XOMA
                                      Ltd and Les Laboratoires Servier to develop and commercialize XOMA 052. In addition, Menarini
                                      Group has entered into a licensing agreement with Ipsen to market Adenuric (febuxostat) in 41
                                      countries including Europe, Russia, and countries west of Russia. These strategic consolidations
                                      have allowed pharmaceutical companies such as Ipsen Pharmaceuticals, Menarini Group, 3SBio
                                      and XOMA Ltd to enter the market.
                                      These strategic consolidations will help the acquirer and licensee companies to diversify their
                                      profiles by entering into the gout therapeutics market, which will in turn make the market more
                                      competitive. These consolidations will also help the companies to generate revenues, thereby
                                      increasing the total revenue of the global gout therapeutics market.




Gout Therapeutics Market to 2017- Entry of Novel Therapies                                                  GBIHC099MR /Published APR 2011
such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market
                                                                                                                                        Page 2
                                                                         © GBI Research. This is a licensed product and is not to be photocopied
                                      1      Table of Contents
                                      1   Table of Contents ........................................................................................................................ 3
                                          1.1    List of Tables..................................................................................................................... 5
                                          1.2    List of Figures ................................................................................................................... 7
                                      2   Gout Therapeutics Market: Introduction ...................................................................................... 9
                                          2.1    GBI Research Report Guidance ....................................................................................... 9
                                      3   Gout Therapeutics Market: Market Overview ............................................................................ 10
                                          3.1    Introduction ..................................................................................................................... 10
                                             3.1.1    Disease Overview.................................................................................................... 10
                                             3.1.2    Global Market Overview .......................................................................................... 12
                                          3.2    Revenue Forecasts for the Global Gout Therapeutics Market ........................................ 12
                                             3.2.1    Revenue .................................................................................................................. 12
                                             3.2.2    Annual Cost of Treatment (ACT) ............................................................................. 14
                                             3.2.3    Treatment Usage Patterns ...................................................................................... 15
                                      4   Gout Therapeutics Market: Geographic Landscape .................................................................. 21
                                          4.1    Revenue Analysis by Geography .................................................................................... 21
                                          4.2    The US ............................................................................................................................ 23
                                             4.2.1    Revenue .................................................................................................................. 23
                                             4.2.2    Annual Cost of Treatment (ACT) ............................................................................. 24
                                             4.2.3    Treatment Usage Patterns ...................................................................................... 25
                                          4.3    Top Five Countries of Europe ......................................................................................... 31
                                             4.3.1    Revenue .................................................................................................................. 31
                                             4.3.2    Annual Cost of Treatment (ACT) ............................................................................. 32
                                             4.3.3    Treatment Usage Patterns ...................................................................................... 33
                                             4.3.4    The UK .................................................................................................................... 39
                                             4.3.5    Germany .................................................................................................................. 41
                                             4.3.6    France ..................................................................................................................... 43
                                             4.3.7    Italy .......................................................................................................................... 45
                                             4.3.8    Spain ....................................................................................................................... 47
                                          4.4    Japan .............................................................................................................................. 49
                                             4.4.1    Revenue .................................................................................................................. 49
                                             4.4.2    Annual Cost of Treatment (ACT) ............................................................................. 50
                                             4.4.3    Treatment Usage Patterns ...................................................................................... 51
                                      5   Gout Therapeutics Market: Therapeutic Landscape .................................................................. 57
                                          5.1    Gout Therapeutics Market for Acute Gout....................................................................... 57
                                             5.1.1    Introduction .............................................................................................................. 57
                                             5.1.2    Revenue .................................................................................................................. 57
                                             5.1.3    Revenue Analysis by Geography ............................................................................ 59
                                             5.1.4    Annual Cost of Treatment........................................................................................ 61
                                             5.1.5    Annual Cost of Treatment by Geography ................................................................ 62
                                             5.1.6    Treatment Usage Patterns ...................................................................................... 64
                                          5.2    Gout Therapeutics Market for Chronic Gout ................................................................... 70
                                             5.2.1    Introduction .............................................................................................................. 70
                                             5.2.2    Revenue .................................................................................................................. 70
                                             5.2.3    Revenue Analysis by Geography ............................................................................ 72
                                             5.2.4    Annual Cost of Treatment........................................................................................ 74
                                             5.2.5    Annual Cost of Treatment by Geography ................................................................ 75
                                             5.2.6    Treatment Usage Patterns ...................................................................................... 77
                                          5.3    Drivers and Barriers to the Gout Therapeutics Market .................................................... 83
                                             5.3.1    Drivers to the Gout Therapeutics Market ................................................................. 83
                                             5.3.2    Barriers to the Gout Therapeutics Market................................................................ 84
                                      6   Gout Therapeutics Market: Product Pipeline Analysis ............................................................... 85
                                          6.1    Introduction ..................................................................................................................... 85
                                          6.2    Research and Development Pipeline .............................................................................. 85


Gout Therapeutics Market to 2017- Entry of Novel Therapies                                                                              GBIHC099MR /Published APR 2011
such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market
                                                                                                                                                                               Page 3
                                                                                         © GBI Research. This is a licensed product and is not to be photocopied
                                           6.2.1    Overview ................................................................................................................. 85
                                           6.2.2    Pipeline by Clinical Phases of Development ........................................................... 86
                                        6.3    Profiles of Promising Drugs in the Gout Therapeutics Market......................................... 88
                                           6.3.1    ACZ885 ................................................................................................................... 88
                                           6.3.2    Arcalyst.................................................................................................................... 88
                                      7 Gout Therapeutics Market: Company Profiles ........................................................................... 89
                                        7.1    Takeda Pharmaceutical Company Limited ..................................................................... 89
                                           7.1.1    Company Overview ................................................................................................. 89
                                           7.1.2    SWOT Analysis ....................................................................................................... 89
                                        7.2    Savient Pharmaceuticals, Inc. ......................................................................................... 90
                                           7.2.1    Company Overview ................................................................................................. 90
                                           7.2.2    SWOT Analysis ....................................................................................................... 90
                                        7.3    Novartis AG..................................................................................................................... 91
                                           7.3.1    Company Overview ................................................................................................. 91
                                           7.3.2    SWOT Analysis ....................................................................................................... 91
                                        7.4    Regeneron Pharmaceuticals, Inc. ................................................................................... 92
                                           7.4.1    Company Overview ................................................................................................. 92
                                           7.4.2    SWOT Analysis ....................................................................................................... 92
                                        7.5    Teijin Pharma Limited ..................................................................................................... 93
                                           7.5.1    Company Overview ................................................................................................. 93
                                           7.5.2    SWOT Analysis ....................................................................................................... 93
                                      8 Gout Therapeutics Market: Strategic Consolidations................................................................. 94
                                        8.1    Overview ......................................................................................................................... 94
                                        8.2    Mergers and Acquisitions ................................................................................................ 95
                                           8.2.1    Major M&A Deals (2004-2010) ................................................................................ 95
                                           8.2.2    Deal Summary ......................................................................................................... 96
                                           8.2.3    Deals by Deal Value ................................................................................................ 97
                                           8.2.4    Deals by Geography ................................................................................................ 98
                                           8.2.5    Deals by Type.......................................................................................................... 99
                                        8.3    Licensing Agreements .................................................................................................. 100
                                           8.3.1    Major Licensing Deals ........................................................................................... 100
                                           8.3.2    Deal Summary ....................................................................................................... 100
                                           8.3.3    Deals by Geography .............................................................................................. 102
                                      9 Gout Therapeutics Market: Appendix ...................................................................................... 103
                                        9.1    Market Definitions ......................................................................................................... 103
                                        9.2    Abbreviations ................................................................................................................ 103
                                        9.3    Research Methodology ................................................................................................. 104
                                           9.3.1    Coverage ............................................................................................................... 104
                                           9.3.2    Primary Research .................................................................................................. 105
                                           9.3.3    Forecasts ............................................................................................................... 105
                                           9.3.4    Expert Panel Validation ......................................................................................... 108
                                        9.4    Contact Us .................................................................................................................... 108
                                        9.5    Disclaimer ..................................................................................................................... 108
                                        9.6    Sources ......................................................................................................................... 108




Gout Therapeutics Market to 2017- Entry of Novel Therapies                                                                           GBIHC099MR /Published APR 2011
such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market
                                                                                                                                                                          Page 4
                                                                                       © GBI Research. This is a licensed product and is not to be photocopied
                                      1.1     List of Tables
                                      Table 1:    Gout Therapeutics Market, Global, Revenue Forecasts, ($m), 2002-2010 .................... 13
                                      Table 2:    Gout Therapeutics Market, Global, Revenue Forecasts, ($m), 2010-2017 .................... 13
                                      Table 3:    Gout Therapeutics Market, Global, Annual Cost of Treatment, ($), 2002-2010 ............. 14
                                      Table 4:    Gout Therapeutics Market, Global, Annual Cost of Treatment, ($), 2010-2017 ............. 14
                                      Table 5:    Gout Therapeutics Market, Global Treatment Usage Patterns (‘000), 2002-2010 ......... 15
                                      Table 6:    Gout Therapeutics Market, Global Treatment Usage Patterns (‘000), 2010-2017 ......... 16
                                      Table 7:    Gout Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010 22
                                      Table 8:    Gout Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2017 22
                                      Table 9:    Gout Therapeutics Market, the US, Revenue Forecasts ($m), 2002-2010 .................... 23
                                      Table 10:   Gout Therapeutics Market, the US, Revenue Forecasts ($m), 2010-2017 .................... 23
                                      Table 11:   Gout Therapeutics Market, the US, Annual Cost of Treatment ($), 2002-2010.............. 24
                                      Table 12:   Gout Therapeutics Market, the US, Annual Cost of Treatment ($), 2010-2017.............. 24
                                      Table 13:   Gout Therapeutics Market, the US, Treatment Usage Patterns (‘000), 2002-2010 ........ 25
                                      Table 14:   Gout Therapeutics Market, the US, Treatment Usage Patterns (‘000), 2010-2017 ........ 26
                                      Table 15:   Gout Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($m),
                                                  2002-2010 ...................................................................................................................... 31
                                      Table 16:   Gout Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($m),
                                                  2010-2017 ...................................................................................................................... 31
                                      Table 17:   Gout Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($),
                                                  2002-2010 ...................................................................................................................... 32
                                      Table 18:   Gout Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($),
                                                  2010-2017 ...................................................................................................................... 32
                                      Table 19:   Gout Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns
                                                  (‘000), 2002-2010 ........................................................................................................... 33
                                      Table 20:   Gout Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns
                                                  (‘000), 2010-2017 ........................................................................................................... 34
                                      Table 21:   Gout Therapeutics Market, the UK, Revenue Forecasts, ($m), 2002- 2010 .................. 39
                                      Table 22:   Gout Therapeutics Market, the UK, Revenue Forecasts, ($m), 2010- 2017 .................. 39
                                      Table 23:   Gout Therapeutics Market, the UK, Prescription Population (‘000), 2002- 2010 ............ 40
                                      Table 24:   Gout Therapeutics Market, the UK, Prescription Population (‘000), 2010- 2017 ............ 40
                                      Table 25:   Gout Therapeutics Market, Germany, Revenue Forecasts, ($m), 2002- 2010............... 41
                                      Table 26:   Gout Therapeutics Market, Germany, Revenue Forecasts, ($m), 2010- 2017............... 41
                                      Table 27:   Gout Therapeutics Market, Germany, Prescription Population (‘000), 2002- 2010 ........ 42
                                      Table 28:   Gout Therapeutics Market, Germany, Prescription Population (‘000), 2010- 2017 ........ 42
                                      Table 29:   Gout Therapeutics Market, France, Revenue Forecasts, ($m), 2002-2010 ................... 43
                                      Table 30:   Gout Therapeutics Market, France, Revenue Forecasts, ($m), 2010-2017 ................... 43
                                      Table 31:   Gout Therapeutics Market, France, Prescription Population (‘000), 2002- 2010 ............ 44
                                      Table 32:   Gout Therapeutics Market, France, Prescription Population (‘000), 2010- 2017 ............ 44
                                      Table 33:   Gout Therapeutics Market, Italy, Revenue Forecasts, ($m), 2002-2010 ....................... 45
                                      Table 34:   Gout Therapeutics Market, Italy, Revenue Forecasts, ($m), 2010-2017 ....................... 45
                                      Table 35:   Gout Therapeutics Market, Italy, Prescription Population (‘000), 2002- 2017 ................ 46
                                      Table 36:   Gout Therapeutics Market, Italy, Prescription Population (‘000), 2010- 2017 ................ 46
                                      Table 37:   Gout Therapeutics Market, Spain, Revenue Forecasts, ($m), 2002-2010 ..................... 47
                                      Table 38:   Gout Therapeutics Market, Spain, Revenue Forecasts, ($m), 2010-2017 ..................... 47
                                      Table 39:   Gout Therapeutics Market, Spain, Prescription Population (‘000), 2002- 2010.............. 48
                                      Table 40:   Gout Therapeutics Market, Spain, Prescription Population (‘000), 2010- 2017.............. 48
                                      Table 41:   Gout Therapeutics Market, Japan, Revenue Forecasts ($m), 2002-2010...................... 49
                                      Table 42:   Gout Therapeutics Market, Japan, Revenue Forecasts ($m), 2010-2017...................... 49
                                      Table 43:   Gout Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2010 ............... 50
                                      Table 44:   Gout Therapeutics Market, Japan, Annual Cost of Treatment ($), 2010-2017 ............... 50
                                      Table 45:   Gout Therapeutics Market, Japan, Treatment Usage Patterns (‘000), 2002-2010 ......... 51
                                      Table 46:   Gout Therapeutics Market, Japan, Treatment Usage Patterns (‘000), 2010-2017 ......... 52
                                      Table 47:   Gout Therapeutics Market, Acute Gout, Global Revenue Forecasts ($m), 2002-2010 . 58
                                      Table 48:   Gout Therapeutics Market, Acute Gout, Global Revenue Forecasts ($m), 2010-2017 . 58
                                      Table 49:   Gout Therapeutics Market, Acute Gout, Global Revenue Analysis by Geography ($m),
                                                  2002-2010 ...................................................................................................................... 59
                                      Table 50:   Gout Therapeutics Market, Acu
								
To top